These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 33158630)

  • 1. Demographic, radiographic, molecular and clinical characteristics of primary gliosarcoma and differences to glioblastoma.
    Pierscianek D; Ahmadipour Y; Michel A; Rauschenbach L; Darkwah Oppong M; Deuschl C; Kebir S; Wrede KH; Glas M; Stuschke M; Sure U; Jabbarli R
    Clin Neurol Neurosurg; 2021 Jan; 200():106348. PubMed ID: 33158630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients.
    Zhang G; Huang S; Zhang J; Wu Z; Lin S; Wang Y
    J Neurooncol; 2016 Apr; 127(2):355-62. PubMed ID: 26725096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study of clinico-pathological parameters and O⁶-methylguanine DNA methyltransferase (MGMT) promoter methylation status in the prognostication of gliosarcoma.
    Singh G; Mallick S; Sharma V; Joshi N; Purkait S; Jha P; Sharma MC; Suri V; Julka PK; Mahapatra AK; Singh M; Kale SS; Sarkar C
    Neuropathology; 2012 Oct; 32(5):534-42. PubMed ID: 22380407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of care and outcomes in gliosarcoma: an analysis of the National Cancer Database.
    Frandsen J; Orton A; Jensen R; Colman H; Cohen AL; Tward J; Shrieve DC; Suneja G
    J Neurosurg; 2018 Apr; 128(4):1133-1138. PubMed ID: 28621623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors and clinical outcomes in adult primary gliosarcoma patients: a Surveillance, Epidemiology, and End Results (SEER) analysis from 2004 to 2015.
    Huang Q; Li F; Chen Y; Hong F; Wang H; Chen J
    Br J Neurosurg; 2020 Apr; 34(2):161-167. PubMed ID: 31829033
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results.
    Galanis E; Buckner JC; Dinapoli RP; Scheithauer BW; Jenkins RB; Wang CH; O'Fallon JR; Farr G
    J Neurosurg; 1998 Sep; 89(3):425-30. PubMed ID: 9724117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiotherapy plus concomitant temozolomide in primary gliosarcoma.
    Adeberg S; Bernhardt D; Harrabi SB; Diehl C; Koelsche C; Rieken S; Unterberg A; von Deimling A; Debus J
    J Neurooncol; 2016 Jun; 128(2):341-8. PubMed ID: 27025857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gliosarcoma: a rare variant of glioblastoma multiforme.
    Rizvi S; Asghar AH; Mehboob J
    J Pak Med Assoc; 2010 Sep; 60(9):773-5. PubMed ID: 21381591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
    Li H; Li J; Cheng G; Zhang J; Li X
    Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
    Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
    Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type Glioblastomas.
    Gessler F; Bernstock JD; Braczynski A; Lescher S; Baumgarten P; Harter PN; Mittelbronn M; Wu T; Seifert V; Senft C
    Neurosurgery; 2019 Jan; 84(1):190-197. PubMed ID: 29617848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does the expression of glial fibrillary acid protein (GFAP) stain in glioblastoma tissue have a prognostic impact on survival?
    Ahmadipour Y; Gembruch O; Pierscianek D; Sure U; Jabbarli R
    Neurochirurgie; 2020 Jun; 66(3):150-154. PubMed ID: 32278699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
    Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
    Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-institutional external validation of a novel glioblastoma prognostic nomogram incorporating MGMT methylation.
    Molitoris JK; Rao YJ; Patel RA; Kane LT; Badiyan SN; Gittleman H; Barnholtz-Sloan JS; Bentzen SM; Kruser TJ; Huang J; Mehta MP
    J Neurooncol; 2017 Sep; 134(2):331-338. PubMed ID: 28643151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MGMT-Positive vs MGMT-Negative Patients With Glioblastoma: Identification of Prognostic Factors and Resection Threshold.
    Katsigiannis S; Grau S; Krischek B; Er K; Pintea B; Goldbrunner R; Stavrinou P
    Neurosurgery; 2021 Mar; 88(4):E323-E329. PubMed ID: 33432978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between glioblastoma cell-derived vessels and poor prognosis of the patients.
    Mei X; Chen YS; Zhang QP; Chen FR; Xi SY; Long YK; Zhang J; Cai HP; Ke C; Wang J; Chen ZP
    Cancer Commun (Lond); 2020 May; 40(5):211-221. PubMed ID: 32359215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The predominant expression of cancer stem cell marker ALDH1A3 in tumor infiltrative area is associated with shorter overall survival of human glioblastoma.
    Gan C; Pierscianek D; El Hindy N; Ahmadipour Y; Keyvani K; Sure U; Zhu Y
    BMC Cancer; 2020 Jul; 20(1):672. PubMed ID: 32680476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment and survival of patients harboring histological variants of glioblastoma.
    Ortega A; Nuño M; Walia S; Mukherjee D; Black KL; Patil CG
    J Clin Neurosci; 2014 Oct; 21(10):1709-13. PubMed ID: 24980627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma.
    Schiffgens S; Wilkens L; Brandes AA; Meier T; Franceschi E; Ermani M; Hartmann C; Sandalcioglu IE; Dumitru CA
    Oncotarget; 2016 Aug; 7(34):55169-55180. PubMed ID: 27409829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.